In a June 1, 2017 press release, Exosome Diagnostics, Inc. announced that it will introduce its Exosome Dx Depletion (and/or) Enrichment (EDDE) platform to members of the American Society of Clinical Oncology (ASCO) at the ASCO annual meeting in Chicago (June 2-6). The patented EDDE platform can select exosomes derived from a specific tissue type, and, at the same time, significantly increase the signal to noise for any target. Exosome Diagnostics encourages attendees to stop by its booth to learn more about how the EDDE platform can improve biomarker discovery and patient stratification (booth #25091, nearby the posters section in the ASCO exhibit hall). “The EDDE platform is an important technological achievement to enrich for disease-specific vesicles. We have shown that this enables detection of targets not otherwise measurable on proteins and RNA. We are particularly excited to now combine the EDDE platform with our long RNAseq platform that efficiently enables sequencing of the transcriptome with a focus on mRNA, long non-coding RNA, and other clinically actionable targets from biofluids such as plasma and urine,” says Dr. Johan Skog, Chief Scientific Officer and Founding Scientist of Exosome Diagnostics. “We have already used the EDDE platform for immunotherapy targets like PD-1, as well as neuronal exosomes containing Tau,” continued Dr. Skog.Login Or Register To Read Full Story